Literature DB >> 8422666

Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

M Rubin1, M B Mokyr.   

Abstract

We have shown previously that thymocytes from MOPC-315-tumor-bearing mice treated with low-dose melphalan (L-phenylalanine mustard) (L-PAM TuB mice) are superior to thymocytes from untreated MOPC-315-tumor-bearing mice or thymocytes from untreated normal mice or normal mice treated with low-dose melphalan in their ability to generate an antitumor cytotoxic response following 5-day in vitro stimulation with MOPC-315 tumor cells in the presence of a low concentration of recombinant interleukin-2 (rIL-2) [Mokyr MB, Bartik MM, Ahn M-C (1989) Cancer Res 49; 870]. Here we characterize the rIL-2 requirements for the generation of enhanced antitumor cytotoxicity by L-PAM TuB thymocytes relative to normal thymocytes upon in vitro stimulation with MOPC-315 tumor cells. Specifically, we show that delaying the addition of a low concentration of rIL-2 to 5-day in vitro stimulation cultures of thymocytes resulted in a progressive decline in the generation of antitumor cytotoxicity by both normal and L-PAM TuB thymocytes. However, even when rIL-2 was added on day 2 after culture initiation, thymocytes from L-PAM TuB mice generated a more potent antitumor cytotoxicity than did thymocytes from normal mice. In addition, when rIL-2 was added at the time of culture initiation, replacement of the conditioned medium with fresh medium lacking rIL-2 on day 3 of the 5-day in vitro stimulation culture period eliminated the ability of normal thymocytes, and reduced (but did not eliminate) the ability of L-PAM TuB thymocytes, to generate a significant level of antitumor cytotoxicity. A low concentration of fresh rIL-2 was sufficient to restore completely the generation of antitumor cytotoxicity by normal or L-PAM TuB thymocytes when added to the stimulation cultures immediately after the removal of the rIL-2-containing conditioned medium. The same low concentration of rIL-2 was also sufficient for restoring the generation of antitumor cytotoxicity by cultures of L-PAM TuB thymocytes, but not normal thymocytes, from which the rIL-2-containing medium was removed 1 day earlier. At the same time, conditioned medium from stimulation cultures of L-PAM TuB thymocytes was not superior to conditioned medium from stimulation cultures of normal thymocytes in supporting the generation of antitumor cytotoxicity by either normal or L-PAM TuB thymocytes.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422666     DOI: 10.1007/bf01789129

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

Authors:  D Berd; H C Maguire; P McCue; M J Mastrangelo
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  Pharmacokinetics of recombinant interleukin 2 in humans.

Authors:  M W Konrad; G Hemstreet; E M Hersh; P W Mansell; R Mertelsmann; J E Kolitz; E C Bradley
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

3.  Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.

Authors:  M B Mokyr; M M Bartik; M C Ahn
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

4.  Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

Authors:  M Röllinghoff; B T Rouse; N L Warner
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

5.  Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

Authors:  B Y Takesue; J M Pyle; M B Mokyr
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

6.  Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

Authors:  M B Mokyr; E Barker; L M Weiskirch; B Y Takesue; J M Pyle
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

7.  Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

Authors:  M S Mitchell; J Kan-Mitchell; R A Kempf; W Harel; H Y Shau; S Lind
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

8.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M M Bartik; B A Baumgartel-Scofield; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

Authors:  D Berd; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

View more
  3 in total

1.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

2.  Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.

Authors:  E Masuda; H Maeda
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

3.  Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.

Authors:  C M Krawczyk; S Verstovsek; P Ujházy; D Maccubbin; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.